Treating Adolescents and Young Adults (AYA) with Blood Cancer (Physician)

Credit Available: AANP, ASWB, CME, NCPD

 

Enroll in this Course

FREE

access until June 11, 2025 12:00 am

 

Enroll Now

Activity Description

This webinar will focus on treating adolescents and young adults (AYAs) with blood cancer, including an overview of blood cancers common in AYAs, treatment options, including new and emerging data and the role of clinical trials, and the management of short and long-term effects, as well as unique considerations for AYAs. A list of resources that you can provide to your patients, as well as additional education resources for you will also be provided.

Time to Complete Activity: 1.0 hour

This course is available from:

December 12, 2023 until June 11, 2025

Course Instructors

Sharon M. Castellino MD, MSc Speaker

Professor, Department of Pediatrics, Emory University School of Medicine, Director, Leukemia and Lymphoma Program,  Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA 

Julie A. Wolfson, MD, MSHS Speaker

Associate Professor, Pediatric Hematology-Oncology Institute for Cancer Outcomes and Survivorship Director, AYA Oncology and Oncofertility Program University of Alabama at Birmingham, Birmingham, AL

Target Audience

This activity is intended for hematologist/oncologists, nurses, social workers, and other healthcare professionals involved in the care of patients with blood cancer.

Course content level for social workers: beginner and intermediate

Educational Objectives

After completing this activity, the participant should be better able to:

• • Describe blood cancers common in adolescent and young adults (AYAs)
  • Identify signs and symptoms of common blood cancers in AYAs and diagnostic tests used
  • Explain treatment options, including new and emerging data and the role of clinical trials
  • Discuss the management of short and long-term effects, as well as unique considerations for AYAs
  • List resources to support patients and their caregivers

Accreditation, Support and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and The Leukemia & Lymphoma Society.  Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Social Worker Continuing Education

The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.0 clinical continuing education credit.

The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hour for this activity.

Nurse Practitioner Continuing Education

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.25 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 23116459. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Support Statement

There is no commercial support associated with this CE activity.

Providers

This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc.

Disclosure of Conflicts of Interest Policy

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Sharon M. Castellino, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Bristol Myers Squibb

The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Seagen Inc.

Unlabeled Uses in Pediatrics
Nivolumab
Brentuximab vedotin (BV) (approved in high-risk; front line)
Pembrolizumab (approved in rr/HL)

Julie Anna Wolfson, MD, MSHS, has no relevant financial relationships with ineligible companies to disclose for this educational activity.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Planner
Lauren Berger, MPH
The Leukemia & Lymphoma Society

Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:

Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated.  A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.

About this Activity

Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.